Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT06953661
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Postural Tachycardia Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Stellate ganglion block — PROCEDURE
    Patients will receive a SGB
  • Sham injection of saline — PROCEDURE
    Patients will receive a subcutaneous sham injection of saline
  • Ropivacaine — DRUG
    The SGB group will receive ropivacaine 0.5% 10ml
  • Normal saline — DRUG
    The control group will receive normal saline in the sham injection.

Study Details

This single-center study aims to evaluate both immediate and long-term outcomes of stellate ganglion block (SGB) in a cohort of rigorously phenotyped patients with Postural Tachycardia Syndrome (POTS). By assessing the effects of SGB, this study seeks to determine its viability as an intervention for symptom control in POTS.

Key Dates

Start date
Oct 13, 2025
Status verified
Oct 2025
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention Group (stellate ganglion block)
    Patients will receive an ultrasound guided stellate ganglion block (SGB) with 10 ml of 0.5% ropivacaine.
  • Sham Comparator: Control Group (sham injection with saline)
    Patients will receive a subcutaneous sham injection with saline. Ultrasound imaging will be used to simulate the guidance process as in the active procedure, maintaining consistency in the procedural experience.

Primary Outcome Measure

COMPASS 31 total score [ Time Frame: Baseline (day -21 to -1 before intervention), first follow-up (day 1 to 21 after the intervention) and second follow-up (day 74 to 94 after the intervention) ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Stanford UniversityStanfordCalifornia94305-
Stanford University School of MedicineStanfordCalifornia94304-

Find similar trials in Stanford, CA

By research site
Stanford University· Stanford, CAStanford University School of Medicine· Stanford, CA

Related Studies